Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Conditions: Metastatic Pancreatic Adenocarcinoma; Refractory Malignant Solid Neoplasm; Stage IV Pancreatic Cancer AJCC v8
Interventions: Drug: Chemotherapy; Drug: Disulfiram; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 13, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments